HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Value in cancer care must ‘start with patients, not dollars’
• Findings demonstrate new ways to exploit immune system to treat cancer Kunle Odunsi, MD, PhD, FRCOG, FACOG
• Incorporating patient-reported outcomes optimally into clinical trials remains challenging Heidi D. Klepin, MD, MS
• Now is the time to make patient-reported outcomes mandatory component of clinical trials Deborah Watkins Bruner, RN, PhD, FAAN
• Patient-reported outcomes may not be appropriate primary, secondary endpoints in every trial Carolyn Gotay, PhD
• Patient-reported outcomes must play critical role in oncology value frameworks Ethan Basch, MD
• ASCO to honor researchers, scientists at annual meeting
• Association elects 11 fellows of the AACR Academy
• Dana-Farber Cancer Institute names pediatric oncology department chair
• Foundation honors Vanderbilt-Ingram Cancer Center director
• Fox Chase Cancer Center staff receive recognition
• Hematology/Oncology Pharmacy Association presents awards
• New ASCO president: Society must help oncologists thrive while focusing on patients’ best interests
• NYU Langone appoints thoracic medical oncology director
• Siteman Cancer Center director to serve as NCCN board chairman
• The Wistar Institute appoints two assistant professors
• Prostate Cancer Drugs in the Pipeline
• Mr. Spock, Dr. Sheldon Cooper and the Rain Man (patient-reported outcomes) Derek Raghavan, MD, PhD, FACP, FRACP, FASCO
• FDA grants breakthrough therapy designation to Keytruda for Hodgkin lymphoma
• FDA approves Cabometyx to treat advanced renal cell carcinoma
• FDA approves Gilotrif for advanced squamous cell carcinoma of the lung
• FDA approves Lumason for hepatic lesions in adults, children
• FDA grants Keytruda priority review for treatment of HNSCC
• FDA grants orphan drug designation to VAL-083 for ovarian cancer
• FDA grants priority review to Opdivo for classical Hodgkin lymphoma
• FDA grants priority review to atezolizumab for PD-L1–positive NSCLC
• A 57-year-old man with squamous cell carcinoma metastases in unusual sites Munir Ghesani, MD, FACNM; Ajit Karakbelkar, MD
• Shooting for the moon: Reasons for optimism in oncology practice William Wood, MD
• ACS issues new care guidelines for survivors of colorectal cancer
• Age, smoking history among predictors of occult cancer after unprovoked VTE
• Alectinib highly active in advanced ALK-positive NSCLC
• Autologous, nonmyeloablative HSCT show promise for advanced multiple myeloma
• Breast cancer incidence, mortality rates vary by location
• Daratumumab demonstrates single-agent activity in relapsed, refractory multiple myeloma
• Donor MBL, CLL status does not raise risk for CLL following transfusion
• Drinking coffee may improve survival for patients with colon cancer
• Enzalutamide superior to bicalutamide for castration-resistant prostate cancer
• FDA initiates anti-tobacco campaign aimed at LGBT young adults
• Hormone therapy appears safe for women on anticoagulants
• Hospital expenditures among dying patients with cancer highest in US, Canada, Norway
• Immune-related adverse events do not impact melanoma survival, time to treatment failure
• Incidence of lymphocytosis linked to higher dasatinib response rate in CML
• Intermittent ADT fails to reduce long-term events in metastatic prostate cancer
• Mediterranean diet plus extra virgin olive oil may reduce breast cancer risk
• Nedaplatin, docetaxel improve OS in advanced, relapsed squamous NSCLC
• Nexavar well tolerated in metastatic medullary thyroid carcinoma
• Ofatumumab maintenance extends PFS, time to next treatment in relapsed CLL
• Oral contraceptive use associated with improved survival in ovarian cancer
• PALB2 mutations may increase risk for breast cancer mortality
• Patients with chronic ITP may have increased infection risk before diagnosis
• Presence of HPV-16 may increase HNSCC risk
• Recombinant coagulation Factor IX albumin fusion protein shows promise for hemophilia B
• Refocusing public narrative necessary to raise ‘alarmingly low’ HPV vaccination rates
• Second malignancy rates remain high among Hodgkin’s lymphoma survivors
• Sulindac, erlotinib reduces polyps in patients with familial adenomatous polyposis
• Temsirolimus demonstrates short-lived activity in primary CNS lymphoma
• Tumor biology may explain racial disparities in clear cell RCC survival
• BGB-283 effective against tumors with BRAF, RAS mutations
• Biden: Realignment of research incentives key to cancer moonshot initiative
• Clinically diagnosed tumors linked to improvements in cancer-specific survival
• Low-fat diet may reduce mortality among women with breast cancer
• MammaPrint helps predict benefit of adjuvant chemotherapy in early-stage breast cancer
• Necitumumab benefit greatest in patients with EGFR–expressing NSCLC
• Nivolumab–ipilimumab combination should be considered standard of care
• Oral bacteria may increase risk for pancreatic cancer
• Palbociclib exhibits antiproliferative activity in untreated early-stage breast cancer
• Management of chemotherapy-induced peripheral neuropathy requires personalized approach Jai N. Patel, PharmD, BCOP, CPP